Study identifier:D910VC00001
ClinicalTrials.gov identifier:NCT05301842
EudraCT identifier:2021-003822-54
CTIS identifier:N/A
A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with TACE Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)
Hepatocellular Carcinoma
Phase 3
No
Tremelimumab, Durvalumab, Lenvatinib
All
725
Interventional
18 Years - 120 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Arm A Tremelimumab, Durvalumab and Lenvatinib in combination with Transarterial Chemoembolization (TACE) | Drug: Tremelimumab Tremelimumab IV (intravenous) Other Name: MEDI1123 Drug: Durvalumab Durvalumab IV (intravenous) Other Name: MEDI4736 Procedure/Surgery: Transarterial Chemoembolization (TACE) TACE (chemo and embolic agent injection into the hepatic artery) Other Name: DEB-TACE and cTACE Drug: Lenvatinib Lenvatinib (oral) Other Name: Lenvima |
Experimental: Arm B Tremelimumab and Durvalumab in combination with Transarterial Chemoemobolization (TACE) | Drug: Tremelimumab Tremelimumab IV (intravenous) Other Name: MEDI1123 Drug: Durvalumab Durvalumab IV (intravenous) Other Name: MEDI4736 Procedure/Surgery: Transarterial Chemoembolization (TACE) TACE (chemo and embolic agent injection into the hepatic artery) Other Name: DEB-TACE and cTACE |
Active Comparator: Arm C Transarterial Chemoembolization (TACE) | Procedure/Surgery: Transarterial Chemoembolization (TACE) TACE (chemo and embolic agent injection into the hepatic artery) Other Name: DEB-TACE and cTACE |